Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

Lancet

Volumn 369, Issue 9579, 2007, Pages 2097-2105

  Kaplitt, Michael G ^a   Feigin, Andrew ^b,c   Tang, Chengke ^b   Fitzsimons, Helen L ^d   Mattis, Paul ^b   Lawlor, Patricia A ^e   Bland, Ross J ^d   Young, Deborah ^e   Strybing, Kristin ^a   Eidelberg, David ^b,c   During, Matthew J ^a,e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Neurologix   (United States)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUTAMATE DECARBOXYLASE; PARVOVIRUS VECTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE; VIRAL GENE THERAPY;

EID: 34250683023     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60982-9     Document Type: Article

References (31)

1. Somia N., and Verma I. Gene therapy: trials and tribulations. Nat Rev Genet 1 (2000) 91-99
2. Manno C., Pierce G., Arruda V., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12 (2006) 342-347
3. Pulkkanen K., and Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 12 (2005) 585-598
4. McPhee S., Janson C., Li C., et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 8 (2006) 577-588
5. Tuszynski M., Thal L., Pay M., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11 (2005) 551-555
6. Obeso J., Rodriguez-Oroz M., Rodriguez M., et al. Pathophysiologic basis of surgery for Parkinson's disease. Neurology 55 suppl 6 (2000) S7-s12
7. Wichmann T., and DeLong M. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann N Y Acad Sci 991 (2003) 199-213
8. Lang A., and Lozano A. Parkinson's disease. First of two parts. N Engl J Med 339 (1998) 1044-1053
9. Nutt J., and Wooten G. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 353 (2005) 1021-1027
10. Erlander M., Tillakaratne N., Feldblum S., Patel N., and Tobin A. Two genes encode distinct glutamate decarboxylases. Neuron 7 (1991) 91-100
11. Hamani C., Saint-Cyr J., Fraser J., Kaplitt M., and Lozano A. The subthalamic nucleus in the context of movement disorders. Brain 127 (2004) 4-20
12. Emborg M., Carbon M., Holden J., et al. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 27 (2007) 501-509
13. Kaplitt M., Leone P., Samulski R., et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8 (1994) 148-154
14. Lee B., Lee H., Nam Y., Oh J., Cho Y., and Chang J. Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene Ther 12 (2005) 1215-1222
15. Luo J., Kaplitt M., Fitzsimons H., et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298 (2002) 425-429
16. Hoehn M. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 10 (1992) 331-339
17. Metman L., Myre B., Verwey N., et al. Test-retest reliability of UPDRS-III, dyskinesia scales, and timed motor tests in patients with advanced Parkinson's disease: an argument against multiple baseline assessments. Mov Disord 19 (2004) 1079-1084
18. Schwab R, England A. Projection technique for evaluating surgery in Parkinson's disease. Third symposium on Parkinson's disease 1969, Edinburgh: 152-157.
19. Asanuma K., Tang C., Ma Y., et al. Network modulation in the treatment of Parkinson's disease. Brain 129 (2006) 2667-2678
20. Hobson D., Lang A., Martin W., Razmy A., Rivest J., and Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 287 (2002) 455-463
21. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., and Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6 (1999) 1574-1583
22. Palombo E., Porrino L., Bankiewicz K., Crane A., Sokoloff L., and Kopin I. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J Neurosci 10 (1990) 860-869
23. Herzog R., Hagstrom J., Kung S., et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 94 (1997) 5804-5809
24. Eidelberg D., Moeller J., Kazumata K., et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 120 (1997) 1315-1324
25. Eidelberg D., Moeller J., Ishikawa T., et al. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. Ann Neurol 39 (1996) 450-459
26. Su P., Ma Y., Fukuda M., et al. Metabolic changes following subthalamotomy for advanced Parkinson's disease. Ann Neurol 50 (2001) 514-520
27. Fukuda M., Mentis M., Ma Y., et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain 124 (2001) 1601-1609
28. Oh M., Abosch A., Kim S., Lang A., and Lozano A. Long-term hardware-related complications of deep brain stimulation. Neurosurgery 50 (2002) 1268-1274
29. Kleiner-Fisman G., Herzog J., Fisman D., et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21 suppl 14 (2006) S290-S304
30. Deuschl G., Schade-Brittinger C., Krack P., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355 (2006) 896-908
31. Simuni T., Jaggi J., Mulholland H., et al. Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety. J Neurosurg 96 (2002) 666-672